TRIAZINE BASED RADIOPHARMACEUTICALS AND RADIOIMAGING AGENTS

Compounds according to Formula I and Formula II are potent inhibitors of PSMA.orPharmaceutical compositions may include a complex of a radionuclide and a Formula I compound or a Formula II compound. Methods include using the radionuclide complex of a Formula I compound or a Formula II compound for t...

Full description

Saved in:
Bibliographic Details
Main Authors LU, GENLIANG, BABICH, JOHN, W, JOYAL, JOHN, ZIMMERMAN, CRAIG
Format Patent
LanguageEnglish
French
German
Published 25.05.2016
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online AccessGet full text

Cover

More Information
Summary:Compounds according to Formula I and Formula II are potent inhibitors of PSMA.orPharmaceutical compositions may include a complex of a radionuclide and a Formula I compound or a Formula II compound. Methods include using the radionuclide complex of a Formula I compound or a Formula II compound for treating or diagnosis of a disease or a condition associated with PSMA activity.
Bibliography:Application Number: EP20140738117